Nanocarriers for methotrexate delivery/codelivery in the frame of cancer diagnostics and treatment: a review

Mahwash Mukhtar; Amanda-Lee Ezra Manicum; Masoumeh Shojaei Barjouei; Rahime Eshaghi Malekshah; Razieh Behzadmehr; Abbas Rahdar; Suresh Ghotekar; Francesco Baino

doi:10.3389/fbiom.2023.1200670

Frontiers in Biomaterials Science (Jun 2023)

Nanocarriers for methotrexate delivery/codelivery in the frame of cancer diagnostics and treatment: a review

Mahwash Mukhtar,
Amanda-Lee Ezra Manicum,
Masoumeh Shojaei Barjouei,
Rahime Eshaghi Malekshah,
Razieh Behzadmehr,
Abbas Rahdar,
Suresh Ghotekar,
Francesco Baino

Affiliations

Mahwash Mukhtar: Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary
Amanda-Lee Ezra Manicum: Department of Chemistry, Faculty of Science, Tshwane University of Technology (Arcadia Campus), Pretoria, South Africa
Masoumeh Shojaei Barjouei: Department of Biology, Faculty of Science, Nour Danesh Institute of Higher Education, Meymeh, Isfahan, Iran
Rahime Eshaghi Malekshah: Medical Biomaterial Research Centre (MBRC), Tehran University of Medical Sciences, Tehran, Iran
Razieh Behzadmehr: Department of Radiology, Zabol University of Medical Sciences, Zabol, Iran
Abbas Rahdar: Department of Physics, University of Zabol, Zabol, Iran
Suresh Ghotekar: Department of Chemistry, Smt. Devkiba Mohansinhji Chauhan College of Commerce and Science, University of Mumbai, Mumbai, India
Francesco Baino: Department of Applied Science and Technology, Institute of Materials Physics and Engineering, Politecnico di Torino, Turin, Italy

DOI: https://doi.org/10.3389/fbiom.2023.1200670
Journal volume & issue: Vol. 2

Abstract

Read online

Cancer is one of the most life-threatening family of diseases that cause death worldwide. As a highly researched and successful therapeutic agent, methotrexate (MTX) treats many solid tumours, hematologic malignancies, and autoimmune illnesses. Despite many benefits, methotrexate induces drug resistance and limits plasma half-life due to its poor pharmacokinetics. The variable biological availability have prompted researchers to investigate innovative delivery strategies for enhancing its therapeutic qualities. To develop more suitable methotrexate formulations, nanoparticles (NPs) have recently gained a significant interest. A wide range of nanoparticles, including polymer-based nanoparticles, carbon-based nanoparticles, lipid-based nanoparticles, as well as inorganic nanoparticles, can be deliver cancer chemotherapeutics such as methotrexate. Loading methotrexate into NPs can provide a delivery system that has shown great promise to carcinoma therapy. In this review, we will describe the feasibility of NP-based strategies to deliver methotrexate in cancer therapy, outlining the current state of the art and the challenges/promises for the future.

Published in Frontiers in Biomaterials Science

ISSN: 2813-3749 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Technology: Chemical technology: Biotechnology
Website: https://www.frontiersin.org/journals/biomaterials-science

About the journal

Abstract

Keywords